Dialog Box

Loading...

Brentuximab vedotin (Adcetris)

Brentuximab Vedotin is an immunotherapy and chemotherapy combined into one medicine used to treat Anaplastic Large Cell Lymphoma and Hodgkin Lymphoma with a promising outlook in treatment of other subtypes of lymphoma. Brentuximab Vedotin works by targeting a particular marker on the cell which is referred to as CD30.

It works by destroying particular areas in the cell and this causes the cell to die.
Brentuximab Vedotin is given by intravenous infusion which means it goes directly into the vein through a needle in your arm or through a central line if you have one in place. Brentuximab Vedotin is given every three weeks either alone or in combination with chemotherapy depending on your subtype and disease status of lymphoma.

Brentuximab Vedotin has the following side effects:
• Lowering of blood counts
• Nausea
• Peripheral neuropathy (numbness and tingling of the hands and feet)
• Tiredness
Brentuximab Vedotin is approved by the TGA for the following indications:
• Relapsed or refractory systemic Anaplastic Large Cell Lymphoma
• Relapsed or refractory Hodgkin’s Lymphoma

Brentuximab Vedotin is listed on the PBS for the following indications:
• Relapsed or refractory systemic Anaplastic Large Cell Lymphoma
• Relapsed or refractory Hodgkin’s Lymphoma